-
Ferring announces European launch of CORTIMENT®MMX® (budesonide) for ulcerative colitis, and new data re-confirms safety and efficacy
-Ferring Pharmaceuticals announced today the European launch of CORTIMENT®MMX® (budesonide), the first…
-
Ferring Pharmaceuticals acquires two phase III ready orthobiologic product candidates from BioSET
-Ferring Pharmaceuticals announced today that it has acquired the assets of BioSurface Engineering Technologies, Inc. (BioSET)…
-
Ferring Pharmaceuticals moves to strengthen growth with appointment of Chief Medical and Chief Scientific officers
-Ferring Pharmaceuticals announced today the appointment of Pascal Danglas, MD as Executive Vice President and Chief Medical Officer…
PRESS RELEASE 2015
PRESS RELEASE 2015